The effect of future ambient air pollution on human premature mortality to 2100 using output from the ACCMIP model ensemble

Raquel A. Silva¹, J. Jason West¹, Jean-François Lamarque², Drew T. Shindell³, William J. Collins⁴, Stig Dalsoren⁵, Greg Faluvegi⁶, Gerd Folberth⁷, Larry W. Horowitz⁸, Tatsuya Nagashima⁹, Vaishali Naik¹⁰, Steven T. Rumbold¹⁴, Kengo Sudo¹¹, Toshihiko Takemura¹², Daniel Bergmann¹³, Philip Cameron-Smith¹³, Irene Cioni¹⁴, Ruth M. Doherty¹⁵, Veronika Eyring¹⁶, Beatrice Josse¹⁷, I. A. MacKenzie¹⁵, David Plummer¹⁸, Mattia Righi¹⁶, David S. Stevenson¹⁵, Sarah Strode¹⁹,²⁰, Sophie Szopa²¹ and Guang Zeng²²

¹Environmental Sciences and Engineering, University of North Carolina, Chapel Hill, North Carolina, USA  
²NCAR Earth System Laboratory, National Center for Atmospheric Research, Boulder, Colorado, USA  
³Nicholas School of the Environment, Duke University, Durham, North Carolina, USA  
⁴Department of Meteorology, University of Reading, Reading, United Kingdom  
⁵CICERO, Center for International Climate and Environmental Research-Oslo, Oslo, Norway  
⁶NASA Goddard Institute for Space Studies and Columbia Earth Institute, New York, New York, USA  
⁷Met Office Hadley Centre, Exeter, United Kingdom  
⁸NOAA Geophysical Fluid Dynamics Laboratory, Princeton, New Jersey, USA  
⁹National Institute for Environmental Studies, Tsukuba, Japan  
¹⁰UCAR/NOAA Geophysical Fluid Dynamics Laboratory, Princeton, New Jersey, USA  
¹¹Earth and Environmental Science, Graduate School of Environmental Studies, Nagoya University, Nagoya, Japan  
¹²Research Institute for Applied Mechanics, Kyushu University, Fukuoka, Japan  
¹³Lawrence Livermore National Laboratory, Livermore, California, USA  
¹⁴Agenzia Nazionale per le Nuove Tecnologie, l’Energia e lo Sviluppo Economico Sostenibile (ENEA), Bologna, Italy  
¹⁵School of GeoSciences, University of Edinburgh, Edinburgh, United Kingdom  
¹⁶Deutsches Zentrum für Luft- und Raumfahrt (DLR), Institut für Physik der Atmosphäre, Oberpfaffenhofen, Germany  
¹⁷GAME/CNRM, Météo-France, CNRS—Centre National de Recherches Météorologiques, Toulouse, France  
¹⁸Canadian Centre for Climate Modeling and Analysis, Environment Canada, Victoria, British Columbia, Canada  
¹⁹NASA Goddard Space Flight Center, Greenbelt, Maryland, USA  
²⁰Universities Space Research Association, Columbia, Maryland, USA  
²¹Laboratoire des Sciences du Climat et de l’Environnement, LSCE-CEA-CNRS-UVSQ, Gif-sur-Yvette, France  
²²National Institute of Water and Atmospheric Research, Lauder, New Zealand  
*Now at National Centre for Atmospheric Science (NCAS), University of Reading, Reading, United Kingdom  

Correspondence to: J. J. West (jjwest@email.unc.edu)

Abstract. Ambient air pollution from ground-level ozone and fine particulate matter (PM2.5) is associated with premature mortality. Future concentrations of these air pollutants will be driven by natural and anthropogenic emissions and by climate change. Using anthropogenic and biomass burning emissions projected in the four Representative Concentration Pathway scenarios (RCPs), the ACCMIP ensemble of chemistry-climate models simulated future concentrations of ozone and PM2.5 at selected decades between 2000 and 2100. We use output from the ACCMIP ensemble, together with projections of future population and baseline mortality rates, to quantify the human premature mortality impacts of future ambient air pollution. Future air pollution-related premature mortality in 2030, 2050 and 2100 is estimated for each scenario and for each model using a health impact function based on
changes in concentrations of ozone and PM$_{2.5}$ relative to 2000 and projected future population and baseline mortality rates. Additionally, the global mortality burden of ozone and PM$_{2.5}$ in 2000 and each future period is estimated relative to 1850 concentrations, using present-day and future population and baseline mortality rates. The change in future ozone concentrations relative to 2000 is associated with excess global premature mortality in some scenarios/periods, particularly in RCP8.5 in 2100 (316 thousand deaths/year), likely driven by the large increase in methane emissions and by the net effect of climate change projected in this scenario, but it leads to considerable avoided premature mortality for the three other RCPs. However, the global mortality burden of ozone markedly increases from less than 0.4 million deaths/year in 2000 to between 1.09 and 2.36 million deaths/year in 2100, across RCPs, mostly due to the effect of increases in population and baseline mortality rates. Decreases in PM$_{2.5}$ concentrations relative to 2000 are associated with avoided premature mortality in all scenarios, particularly in 2100: between -2.39 and -1.31 million deaths/year for the four RCPs due to the reductions in emissions projected in these scenarios. The global mortality burden of PM$_{2.5}$ is estimated to decrease from 1.7 million deaths/year in 2000 to between 0.95 and 1.55 million deaths/year in 2100 for the four RCPs, due to the combined effect of decreases in PM$_{2.5}$ concentrations and changes in population and baseline mortality rates. Trends in future air pollution-related mortality vary regionally across scenarios, reflecting assumptions for economic growth and air pollution control specific to each RCP and region.

Mortality estimates differ among chemistry-climate models due to differences in simulated pollutant concentrations, and is the greatest contributor to overall mortality uncertainty for most cases assessed here, supporting the use of model ensembles to characterize uncertainty. Increases in exposed population and baseline mortality rates of respiratory diseases magnify the impact on premature mortality of changes in future air pollutant concentrations and explain why the future global mortality burden of air pollution can exceed the current burden, even where air pollutant concentrations decrease.

1 Introduction

Ambient air pollution has adverse effects on human health, including premature mortality. Exposure to ground-level ozone is associated with respiratory mortality (e.g. Bell et al., 2005; Gryparis et al., 2004; Jerrett et al., 2009; Levy et al., 2005). Exposure to fine particulate matter with aerodynamic diameter less than 2.5 µm (PM$_{2.5}$) is associated with mortality due to cardiopulmonary diseases and lung cancer (e.g. Brook et al., 2010; Burnett et al., 2014; Hamra et al., 2014; Krewski et al., 2009; Lepeule et al., 2012). Previous studies have estimated the present-day global burden of disease due to exposure to ambient ozone and PM$_{2.5}$ (e.g., Evans et al., 2013; Lim et al., 2012), with several studies estimating this burden using only output of global atmospheric models (Anenberg et al., 2010; Fang et al., 2013; Lelieveld et al., 2013; Rao et al., 2012, Silva et al., 2013). However, few studies have evaluated how the global burden might change in future scenarios (e.g. Lelieveld et al., 2015; Likhvar et al., 2015).

Future ambient air quality will be influenced by changes in emissions of air pollutants and by climate change. Changes in anthropogenic emissions will likely dominate in the near-term (Kirtman et al., 2013 and references therein), and depend on several socio-economic factors including economic growth, energy demand, technological choices and developments, demographic trends and land use change, as well as air quality and climate policies. Climate change will affect the ventilation, dilution, and removal of air pollutants, the frequency of stagnation, photochemical reaction
rates, stratosphere–troposphere exchange of ozone, and natural emissions (Fiore et al., 2012, 2015; Jacob and Winner, 2009; von Schneidemesser et al., 2015; Weaver et al., 2009). Climate change is likely to increase ozone in polluted regions during the warm season, particularly in urban areas and during pollution episodes. In remote regions, however, ozone is likely to decrease due to greater water vapor concentrations, which increase the loss of ozone by photolysis and subsequent formation of hydroxyl radicals (Doherty et al., 2013). The effects of climate change on PM$_{2.5}$ concentrations are generally uncertain as changes in temperature affect both reaction rates and gas to particle partitioning as well as wildfires and biogenic emissions, and vary regionally primarily due to differing projections of changes in precipitation (Fiore et al., 2012, 2015; Fuzzi et al., 2015; Jacob and Winner, 2009; von Schneidemesser et al., 2015; Weaver et al., 2009).

The Atmospheric Chemistry and Climate Model Intercomparison Project (ACCMIP) simulated preindustrial (1850), present-day (2000) and future (2030, 2050 and 2100) concentrations of ozone and PM$_{2.5}$ with an ensemble of 14 state-of-the-art chemistry climate models (Table S1) (Lamarque et al., 2013, Stevenson et al., 2013) to support the IPCC’s Fifth Assessment Report. Using modeled 1850 and 2000 concentrations from this ensemble, we showed previously that exposure to present-day anthropogenic ambient air pollution is associated with 470 (95% Confidence Interval (CI): 140, 900) thousand deaths/year from ozone-related respiratory diseases, and 2.1 (1.3, 3.0) million deaths/year from PM$_{2.5}$-related cardiopulmonary diseases and lung cancer (Silva et al., 2013). These results were obtained for a wider range of cardiopulmonary diseases and using a different exposure-response model for PM$_{2.5}$ mortality than the present study, as discussed later.

The ACCMIP models simulated future air quality for specific periods through 2100, for four global greenhouse gas (GHG) and air pollutant emission scenarios projected in the Representative Concentration Pathways (RCPs) (Van Vuuren et al., 2011a and references therein). The four RCPs were developed by different research groups with different assumptions regarding the pathways of population growth, economic and technological development, and air quality and climate policies. Anthropogenic radiative forcing in 2100 ranges from a very low level in the mitigation scenario RCP2.6 (Van Vuuren et al., 2011b), to medium levels in the two stabilization scenarios, RCP4.5 (Thomson et al., 2011) and RCP 6.0 (Masui et al., 2011), to a high level in the very high baseline emissions scenario RCP8.5 (Riahi et al., 2011). All RCPs assume increasingly stringent air pollution controls as countries develop economically, leading to decreases in air pollutant emissions that reflect the different methods of the different groups (e.g., Smith et al., 2011), and do not span the range of possible futures published in the literature for short-term species. While most air pollutants are projected to decrease, ammonia increases in all RCPs due to the projected increase in population and food demand, and methane increases in RCP8.5 because of its projected rise in livestock and rice production. However, these scenarios follow different pathways in different regions. In some regions, emissions increase to mid-century before decreasing, while in other regions emissions are already decreasing at present and continue decreasing to 2100. Models in the ACCMIP ensemble incorporate chemistry-climate interactions, including mechanisms by which climate change affects ozone and PM$_{2.5}$, although models do not all include the same mechanisms of interactions and do not always agree on the net effect of these interactions (von Schneidemesser et al., 2015).

Using modeled ozone and PM$_{2.5}$ concentrations from the ACCMIP ensemble, we estimate the future premature human mortality associated with exposure to ambient air pollution. Our premature mortality estimates are obtained using a
health impact function, combining the relative risk of exposure to changes in air pollution with future exposed population and cause-specific baseline mortality rates. We estimate overall future premature mortality considering the difference in air pollution associated with 2030, 2050 and 2100 emissions and climate relative to that resulting from 2000 emissions and climate. Mortality estimates are obtained at a sufficiently fine horizontal resolution (0.5°x0.5°) to capture both global and regional effects and inform regional and national air quality and climate change policy, but are not expected to capture local scale (e.g., urban) air pollution effects.

2 Methods

2.1 Ambient ozone and PM$_{2.5}$ concentrations

Concentrations of ozone and PM$_{2.5}$ in surface air are calculated for the present day (2000) and for the 2030, 2050 and 2100 decades for the four RCPs using the output of simulations by the ACCMIP ensemble of chemistry-climate models. As described by Lamarque et al. (2013) not all models are truly coupled chemistry climate models. OsloCTM2 and MOCAGE are chemical transport models driven by offline meteorological fields, and UM-CAM and STOC-HadAM3 do not model the feedback of chemistry on climate.

All ACCMIP models used nearly identical anthropogenic and biomass burning emissions for the present day and future, but they used different natural emissions (e.g. biogenic volatile organic compounds, ocean emissions, soil and lightning NO$_x$), which mostly impacted emissions of ozone precursors (Lamarque et al., 2013; Young et al., 2013) and natural aerosols (i.e., dust and sea salt). Model output shows good agreement with recent observations, both for ozone (Young et al., 2013) and for PM$_{2.5}$ (Shindell et al., 2013), although models tend to overestimate ozone in the Northern Hemisphere and underestimate it in the Southern Hemisphere, and to underestimate PM$_{2.5}$, particularly in East Asia. Future surface concentrations of air pollutants vary across scenarios and models, but ozone is projected to decrease except in RCP8.5, mostly associated with the large increase in methane concentrations specific to this scenario and the effect of climate change in remote regions (von Schneidemesser et al., 2015; Young et al., 2013).

We obtained hourly and monthly output from the ACCMIP ensemble simulations for a base year (2000) and for future projections under the four RCPs (2030, 2050 and 2100), with each time period corresponding to simulations of up to 10 years, depending on the model. Only two models reported results for all four RCP scenarios and the three future time periods – GFDL-AM3 and GISS-E2-R. PM$_{2.5}$ is calculated as a sum of aerosol species reported by six models (see Supplemental Material), and four of these models also reported their own estimate of total PM$_{2.5}$ (Table S1). Our PM$_{2.5}$ formula includes nitrate; since this species was reported by three models only, we calculate the average nitrate concentrations in each cell reported by these models and add this average to PM$_{2.5}$ for the other models, following Silva et al. (2013). We use our PM$_{2.5}$ estimates to obtain all mortality results, and perform a sensitivity analysis using the PM$_{2.5}$ concentrations reported by four models using their own PM$_{2.5}$ formulas, which differed among models, as reported in Silva et al. (2013). The native grid resolutions of the 14 models varied from 1.9°x1.2° to 5°x5°; we regrid ozone and PM$_{2.5}$ species surface concentrations from each model to a common 0.5°x0.5° horizontal grid.
Ozone and PM$_{2.5}$ concentrations are calculated in each grid cell for each model separately. For both pollutants, we use identical metrics to those reported in the epidemiological studies we considered for the health impact assessment (next section):

- Seasonal average of daily 1-hr maximum ozone concentration, for the six consecutive months with highest concentrations in each grid cell;
- Annual average PM$_{2.5}$ concentration.

Among the 14 models, five models reported only monthly ozone concentrations, while the remaining models reported both hourly and monthly values. We calculate the ratio of the seasonal average of daily 1-hr maximum to the annual average of monthly concentrations, for each scenario/year, for those that reported both hourly and monthly concentrations. Then we apply that ratio to the annual average of monthly ozone concentrations for the former five models, as previously done by Silva et al. (2013). The differences in ozone and PM$_{2.5}$ concentrations between future year (2030, 2050 and 2100) and 2000 are shown in Tables S2 and S3, for each model. For ten world regions (Figure S1), we also estimate regional multi-model averages for each scenario/year (Figures S2 and S3).

### 2.2 Health impact assessment

We estimate future air pollution-related cause-specific premature mortality using similar methods to Silva et al. (2013), except for our use of the recently published Integrated Exposure-Response (IER) model for PM$_{2.5}$ (Burnett et al., 2014) and projections of population and baseline mortality rates from the International Futures (IFs) integrated modeling system (Hughes et al., 2011).

We apply a health impact function to estimate premature mortality associated with exposure to ozone and PM$_{2.5}$ ambient air pollution ($\Delta$Mort) in each grid cell: $\Delta$Mort = $y_0 \times AF \times Pop$, where $y_0$ is the baseline mortality rate (for the exposed population), $AF = 1 - 1/RR$ is the attributable fraction, $RR$ is the relative risk of death attributable to a change in pollutant concentrations, (RR=1 if there is no increased risk of death associated with a change in pollutant concentrations), and $Pop$ is the exposed population (adults aged 25 and older). We take the change in pollutant concentrations due to future emissions and climate as the difference between concentrations in each future year (2030, 2050 and 2100) and in 2000 and calculate the impact of that concentration change on premature mortality. This approach differs from a calculation of the global burden of air pollution-related mortality since we use 2000 rather than 1850 concentrations as baseline. We estimate mortality changes due to future concentration changes, relative to the present, to avoid applying the health impact function at very low concentrations where there is less confidence in the exposure-response relationship. For example, the simulated 1850 air pollutant concentrations are often below the lowest measured value of the American Cancer Society study (Jerrett et al., 2009; Krewski et al., 2009). For illustration, we also estimate mortality relative to 1850 concentrations, which could be regarded as global burden of disease calculations, following Silva et al. (2013).

For each model, we estimate ozone-related mortality due to chronic respiratory diseases (RESP), using RR from Jerrett et al. (2009). We also estimate PM$_{2.5}$-related mortality due to ischemic heart disease (IHD), cerebrovascular disease (STROKE), chronic obstructive pulmonary disease (COPD) and lung cancer (LC), using RRs from the IER model (Burnett et al., 2014). We apply the IER model instead of RRs from Krewski et al. (2009), used by Silva et al. (2013),...
as the newer model should better represent the risk of exposure to PM$_{2.5}$, particularly at locations with high ambient concentrations. In the IER model, the concentration-response function flattens off at higher PM$_{2.5}$ concentrations yielding different estimates of excess mortality for identical changes in air pollutant concentrations in less-polluted vs. highly-polluted locations. Specifically, a one unit reduction of air pollution may have a stronger effect on avoided mortality per million people in regions where pollution levels are lower (e.g. Europe, North America, etc.) compared with highly-polluted areas (e.g. East Asia, India, etc.), which would not be the case for a log-linear function (Jerrett et al. 2009; Krewski et al. 2009). Therefore, using the IER model may result in smaller changes in avoided mortality in highly-polluted areas than using the log-linear model.

Each RCP includes its own projection of total population, but not population health characteristics. For all scenarios, we choose to use a common projection of population and baseline mortality rates per age group from the IFs (Figures S4 and S5). IFs projects population and mortality based on UN and WHO projections from 2010 through 2100, per age group and country, mostly based on three drivers – income, education, and technology (Hughes et al., 2011). Population projections from IFs differ from those underlying each RCP, but lie within the range of the latter (Figure S4). IFs projects rising baseline mortality rates for cardiovascular diseases (CVD) and RESP, globally and in most regions, particularly in East Asia and India, reflecting an aging population. By using projections from IFs, we have a single source of population and baseline mortality rates, assuring their consistency and enabling us to isolate the effect of changes in air pollutant concentrations across the RCPs. Had we used the population projections from each scenario, the magnitude of the changes (increases or decreases in premature mortality relative to 2000) would likely increase in RCP8.5, but decrease in RCP2.6, RCP4.5 and RCP6.0. With the exception of Europe, Former Soviet Union (FSU) and East Asia, where population is projected to decrease in 2100 relative to 2000, had we used present-day population and baseline mortality we would have obtained lower estimates for excess or avoided mortality in each scenario/year, as projected increases in population and baseline mortality magnify the impact of changes in air pollutant concentrations. Therefore, we estimate the overall effect of future air pollution (due to changes in emissions and climate change) considering the population that will potentially be exposed to those effects. We also obtain different estimates of changes in future mortality than if we had calculated the global burden in each year, using air pollutant concentrations, population and baseline mortality rates in that year, and subtracted the present-day burden. Our results do not reflect the potential synergistic effect of a warmer climate on air pollution-related mortality (Wilson et al., 2014 and references therein).

Country-level population projections for 2030, 2050 and 2100 are gridded to 0.5°x0.5° using ArcGIS 10.2 geoprocessing tools, assuming that the spatial distribution of total population within each country is unchanged from the 2011 LandScan Global Population Dataset at approximately 1 km resolution (Bright et al., 2012), and that the exposed population is distributed in the same way as the total population within each country. Ifs projections of mortality rates for CVD are used to estimate baseline mortality rates for IHD and STROKE considering their present-day proportion in CVD (using GBD 2010 baseline mortality rates), as are RESP projections for COPD and malignant neoplasms for LC. We estimate the number of deaths per 5-year age group per country using the country level population. The resulting population and baseline mortality per age group at 30"x30" are regridded to the same 0.5°x0.5° grid as the concentrations of air pollutants.
Uncertainty from the RRs is propagated separately for each model-scenario-year to mortality estimates in each grid cell, through 1000 Monte Carlo (MC) simulations, i.e. we repeat the calculations in each grid cell for 1000 times using random sampling of the RR variable. For ozone, we use the reported 95% Confidence Intervals (CIs) for RR (Jerrett et al., 2009) and assume a normal distribution, while for \( \text{PM}_{2.5} \) we use the parameter values reported by Burnett et al. (2014) for 1000 MC simulations. Then for each of the 1000 simulations, we add mortality over many grid cells to obtain regional and global mortality and estimate the empirical mean and 95% CI of the regional and global mortality results. Uncertainty in air pollutant concentrations is based on the spread of model results by calculating the average and 95% CI for the pooled results of the 1000 MC simulations for each model. We also estimate the contribution of uncertainty in RR and uncertainty in air pollutant concentrations to overall uncertainty in mortality estimates using a tornado analysis. Uncertainties associated with population and baseline mortality rates are not reported by IFs, and are not considered in the uncertainty analysis.

3 Results

First, we present our estimates of ozone and \( \text{PM}_{2.5} \)-related excess/avoided premature mortality in 2030, 2050 and 2100 for changes in pollutant concentrations between 2000 and each future period, for the four RCPs (sections 3.1 and 3.2, Figures 1 to 7). Figures 1 and 4 show global mortality for the different ACCMIP models. The multi-model average mortality results are shown for individual grid cells (Figures 2 and 5) and for regional totals (Figures 3 and 6). Finally, we include our estimates of the global mortality burden of both air pollutants for future concentrations relative to 1850 concentrations (section 3.3, Figures 8 and 9). In some cases, avoided/excess future mortality due to a reduction/increase in future concentrations relative to 2000 concentrations shows a different trend than the global mortality burden, which reflects the combined effects of future changes in concentrations relative to 1850, exposed population and baseline mortality rates.

3.1 Ozone-related future premature mortality

We find that future changes in ozone concentrations are associated with excess global premature mortality due to respiratory diseases in 2030, but avoided mortality by 2100 for all scenarios but RCP8.5 (Figure 1, Table S4). In 2030, all RCPs show excess multi-model average ozone mortality: 11,900 (RCP2.6), 100,000 (RCP4.5), 71,200 (RCP6.0) and 264,000 (RCP8.5) deaths/year. For each RCP, however, some models yield avoided mortality in 2030. In 2050, we estimate avoided ozone mortality for RCP2.6 (-450,000 deaths/year) and RCP4.5 (-360,000 deaths/year) and excess ozone mortality for RCP6.0 (441,000 deaths/year) and RCP8.5 (246,000 deaths/year); these averages are obtained from only 3 or 4 models, depending on the scenario, which makes it difficult to compare with the other two periods. In 2100, we estimate excess ozone mortality in RCP8.5 (316,000 deaths/year), but avoided ozone mortality for the other three RCPs with all models agreeing in sign of the change: -1.02 million (RCP2.6), -917,000 (RCP4.5) and -718,000 (RCP6.0) deaths/year.

For RCP8.5, we propagate input uncertainty to the mortality estimates (Figure 1, Table S4). Global future premature mortality rises from 264,000 (-39,300 to 648,000) deaths in 2030 to 316,000 (-187,000 to 1.38 million) deaths in 2100.

Uncertainty in RR leads to coefficients of variation (CV) ranging from 31 to 37% (2030), 31 to 40% (2050) and 16 to 35% (2010).
47% (2100) for the different models. Considering the spread of model results, overall CV for the multi-model average mortality increases to 66% (2030), 78% (2050) and 125% (2100). While uncertainty in RR and in modeled ozone concentrations have similar contributions to overall uncertainty in mortality results in 2050 (51% and 49%, respectively), in 2030 modeled ozone concentrations are the greatest contributor (81%), and in 2100 uncertainty in RR contributes the most to overall uncertainty (88%). For 2030, HadGEM2 differs in sign from the other 13 models with (avoided) global mortality totalling -33,900 deaths/year. For 2050, LMDzORINCA differs substantially from the other 3 models with -38,900 deaths/year. For 2100, HadGEM2 is a noticeable outlier with 1.2 million excess deaths/year and MOCAGE differs in sign from the other 12 models with -159,000 deaths/year.

Excess ozone-related future premature mortality (Figures 2 and 3, Table S5) is noticeable in some regions through 2030 for all RCPs, particularly in India and East Asia for RCP8.5 (124,000 and 127,000 deaths/year, respectively), but all scenarios except RCP8.5 show avoided global ozone-related mortality in 2100. Under this scenario in 2100, there are increases in ozone concentrations in all regions except North America, East Asia and Southeast Asia (Figure S2), likely driven by the projected large increase in methane emissions as well as by climate change. Avoided mortality in those three regions of over -140,000 deaths/year is outweighed by excess mortality in India (292,000 deaths/year), Africa (128,000 deaths/year) and the Middle East (29,800 deaths/year). Also, some regions show different trends in future mortality relative to 2000 depending on the RCP, reflecting the effects of distinct assumptions in each RCP about economic growth and air pollution control with different trends in regional ozone precursor emissions. For example, North America and Europe show decreases in mortality through 2100 in all scenarios, except a slight increase in Europe for RCP8.5 in 2100. In East Asia, mortality peaks in 2050 for RCP6.0, driven by peak precursor emissions in 2050 in this scenario, but it peaks in 2030 for the other three RCPs. India shows peaks in mortality in 2050 followed by decreases for all RCPs but RCP8.5, in which mortality increases through 2100. Africa shows increases in mortality through 2100 for RCP2.6 and RCP8.5, while it peaks in 2050 for RCP4.5 and decreases through 2100 for RCP6.0. Also, the effect of changes in population and baseline mortality rates is noticeable in some regions when comparing the trends in total ozone-related mortality and mortality per million people in each region (Figure S6). For example, decreases in population projected for 2100 in Europe, FSU and East Asia, are reflected in greater changes in mortality per million people than in total mortality, while the threefold increase in population in Africa amplifies the changes in total mortality.

### 3.2 PM<sub>2.5</sub>-related future premature mortality

Global PM<sub>2.5</sub>-related premature mortality, considering the difference in future concentrations and 2000 concentrations, decreases substantially in most scenarios, particularly in 2100 (Figure 4, Table S6). In 2030, the multi-model average varies from -289,000 (RCP4.5) to 17,200 (RCP8.5) deaths/year, although one model (CICERO-OsloCTM2) shows excess mortality for RCP2.6 and RCP8.5. In 2050, substantial avoided mortality is estimated for all scenarios except RCP6.0 which shows a small increase in mortality (16,700 deaths/year), but this is the average of only three models that do not agree on the sign of the change. In 2100, all scenarios show considerable avoided mortality, reflecting the substantial decrease in emissions of primary PM<sub>2.5</sub> and precursors: -1.93 million (RCP2.6), -2.39 million (RCP4.5), -1.76 million (RCP6.0) and -1.31 million (RCP8.5) deaths/year.
Considering the results of the MC simulations for RCP8.5, premature mortality changes from -17,200 (-386,000 to 661,000) deaths in 2030 to -1.31 (-2.04 to -0.17) million deaths in 2100 (Figure 4, Table S6). Uncertainty in RR leads to a CV of 11 to 191% for the different models in the three future years. The spread of model results increases overall CV to 1644% (2030), 20% (2050) and 41% (2100). Uncertainty in modeled PM$_{2.5}$ concentrations in 2000 is the greatest contributor to overall uncertainty (59% in 2030, 45% in 2050, and 49% in 2100), followed by uncertainty in modeled PM$_{2.5}$ in future years (40% in 2030, 26% in 2050 and 32% in 2100). Uncertainty in RR has a negligible contribution to overall uncertainty in 2030 (<1%), as the multi-model mean mortality change happens to be near zero (one model projects a large increase while the other five models project decreases), but contributes 29% in 2050 and 20% in 2100. In several regions (North America, South America, Europe, FSU and Australia), PM$_{2.5}$ future premature mortality decreases through 2100 for all RCPs (Figures 5 and 6, Table S7). However, in East Asia, Southeast Asia, India, Africa, and the Middle East, for some scenarios, PM$_{2.5}$ mortality increases through 2030 or 2050, before decreasing. In East Asia, mortality peaks in 2030 for RCP8.5 and in 2050 for RCP6.0. In Southeast Asia, mortality peaks in 2030 for RCP2.6 and in 2050 for RCP6.0. In India, mortality peaks in 2030 or 2050 for all RCPs except RCP8.5 which still shows an increase in 2100. In Africa, mortality increases through 2100 for RCP2.6 and RCP8.5, but for RCP4.5 it peaks in 2050 and for RCP6.0 it decreases through 2100. The changes in future mortality reflect changes in future PM$_{2.5}$ concentrations relative to 2000 (Figure S3), and a substantial increase in exposed population through the 21st century, particularly in Africa, India and the Middle East (Figure S4). The decreases in population in Europe, FSU and East Asia have similar effects as those mentioned above for ozone-related mortality. For example, while total avoided mortality in 2100 in East Asia decreases compared to 2050, for RCP2.6, RCP4.5 and RCP8.5, total avoided mortality per million people increases in the same scenarios (Figure S7).

We compared mortality results using our own estimates of PM$_{2.5}$ from the sum of reported species with results using PM$_{2.5}$ reported by four models (Figure 7). The multi-model average future avoided mortality for the four models which reported PM$_{2.5}$ is comparable although lower than the average for our PM$_{2.5}$ estimates for the same models. Individual models do not show the same differences in mortality using their own vs. our PM$_{2.5}$ estimates. Also, for two models (GFDL-AM3 and MIROC-CHEM) the two sources of PM$_{2.5}$ estimates yield mortality changes of different sign in 2030. These results reflect the different aerosol species included by each model to estimate PM$_{2.5}$ (e.g. nitrate is not included by all models).

### 3.3 Global burden on mortality of ozone and PM$_{2.5}$

Here we present estimates of the global burden on mortality of ozone and PM$_{2.5}$ concentrations in the future, considering the four RCPs relative to preindustrial concentrations (1850) and future exposed population and baseline mortality rates (Figures 8 and 9, Tables S8 and S9). For context, we estimate the global burden in 2000 (using present-day population from Landscan 2011 Population Dataset and baseline mortality rates from GBD2010) to be: 382,000 (121,000 to 728,000) ozone deaths/year and 1.70 (1.30 to 2.10) million PM$_{2.5}$ deaths/year. These estimates are 19% lower than those obtained in our previous study (Silva et al., 2013), reflecting more restrictive mortality outcomes (chronic respiratory diseases rather than all respiratory diseases, and IHD+STROKE+COPD rather than all cardiopulmonary diseases), updated population and baseline mortality rates, and the use of the recent IER model.
(Burnett et al., 2014) for PM$_{2.5}$ (instead of Krewski et al., 2009). Compared with the GBD 2010 results, these estimates are 151% higher than ozone-related mortality and 47% lower than PM$_{2.5}$-related mortality reported by Lim et al. (2012), likely due to the fact that we estimate the global mortality burden using 1850 concentrations as baseline, while Lim et al. consider counterfactual concentrations (theoretical minimum-risk exposure) that are mostly higher for ozone (uniform distribution between 33.3 and 41.9 ppb) and lower for PM$_{2.5}$ (uniform distribution between 5.8 and 8.8 µg/m$^3$) than 1850 concentrations.

For ozone, the global mortality burden increases in all RCPs through 2050 to between 1.84 and 2.60 million deaths/year, and then it decreases slightly for RCP8.5 and substantially for the other RCPs, ranging between 1.09 and 2.36 million deaths/year in 2100. The increase can be explained by the rise in the baseline mortality rates for chronic respiratory diseases magnified by the increase in exposed population, while the decline is likely mostly related to the decrease in concentrations, slightly countered by further population growth (Figure 8). The global burden of mortality from PM$_{2.5}$ shows a declining trend for all RCPs from 2030 to 2100, peaking between 2.4 and 2.6 million deaths/year in 2030 then declining to between 0.56 and 1.55 million deaths/year in 2100, except for RCP6.0 which peaks in 2050 (3.50 million deaths/year) before declining considerably. For PM$_{2.5}$, the increase in exposed population and the decline in concentrations have a much greater effect than changes in baseline mortality rates (Figure 9). Our estimates for the global burden of PM$_{2.5}$ mortality in 2050 (between 1.82 and 3.50 million deaths/year for the four RCPs) are considerably lower than those of Lelieveld et al. (2015) (5.87 million deaths/year for IHD+STROKE+COPD+LC), likely due to the assumption in the RCP scenarios of further regulations on air pollutants, while the Business-As-Usual scenario of Lelieveld et al. does not assume regulations beyond those currently defined.

To help explain differences between the trends in future global burden (Figures 8 and 9) and in future mortality relative to 2000 (Figures 1 and 4), we estimate the future global burden for two cases: Case A - using 2000 concentrations relative to 1850 and present-day population but future baseline mortality rates; Case B – using 2000 concentrations relative to 1850 but future population and baseline mortality rates. Case A reflects the effect of future baseline mortality rates on the global burden, if concentrations in future years were maintained at 2000 levels, while Case B reflects the combined effect of population and baseline mortality rates, i.e. it is identical to Case A except that population changes. The difference between the global burden for each RCP and Case B reflects the effects of changes in future air pollutant concentrations, and nearly equals future mortality relative to 2000 concentrations in Figures 1 and 4. However, Cases A and B are calculated for all 14 models for ozone and 6 models for PM$_{2.5}$ (since all models reported air pollutant concentrations in 2000), while future mortality relative to 2000 is calculated for the models that report each scenario/year.

4 Discussion

The importance of conducting health impact assessments with air pollutant concentrations from model ensembles, instead of single models, is highlighted by the differences in sign of the change in mortality among models, and by the marked impact of the spread of model results on overall uncertainty in our mortality estimates. In most cases assessed here (ozone mortality in 2030 relative to 2000, PM$_{2.5}$ mortality in 2030, 2050 and 2100 relative to 2000), uncertainty in modeled air pollutant concentrations is the greatest contributor to uncertainty in mortality estimates.
Uncertainty in future ozone mortality in 2050 relative to 2000 has comparable contributions from uncertainty in RR and in modeled concentrations, while in 2100 uncertainty in RR contributes the most to overall uncertainty in ozone mortality.

There are several uncertainties and assumptions that affect our results. We applied the same RR worldwide and into the future, despite differences in vulnerability of the exposed population, in composition of PM$_{2.5}$, and in other factors that may support the use of different risk estimates or different concentration-response relationships. Also, we estimate mortality for adults aged 25 and older, and do not quantify air pollutant effects on morbidity, so we underestimate the overall impact of changes in pollutant concentrations on human health. Uncertainties in projections of future population and baseline mortality rates were not included in our estimates of uncertainty, and the spread of model results does not account for uncertainty in emissions inventories, as all ACCMIP models used the same central estimate of anthropogenic emissions.

These uncertainties can be addressed through additional long-term epidemiological studies, particularly for large cohorts in developing countries, to improve RR estimates globally. These studies should be representative of wider ranges of exposure and air pollutant mixtures than existing studies in the US and Europe, and they should control for confounding factors such as other environmental exposures, use of air conditioning, socio-economic factors, etc.

Our results are limited by the range of projected air pollutant emissions given by the RCPs. All RCPs consider reductions in anthropogenic precursor emissions associated with more extensive air quality legislation as incomes rise, except for methane in RCP8.5 and for ammonia in all scenarios. These scenarios together do not encompass the range of plausible air pollution futures for the 21st century, as the RCPs were not designed for this purpose (van Vuuren et al., 2011a). Other plausible scenarios have been considered, such as the Current Legislation Emissions and Maximum Feasible Reductions scenarios used by Likhvar et al. (2015) and the Business-As-Usual scenario considered by Lelieveld et al (2015). If economic growth does not lead to stricter air pollution control, emissions and health effects may rise considerably, particularly for scenarios of high population growth in developing countries.

5 Conclusions

Under the RCP scenarios, future PM$_{2.5}$ concentrations are calculated to result in decreased global premature mortality versus what would occur with fixed year-2000 concentrations, but ozone mortality increases in some scenarios/periods. In 2100, excess ozone-related premature mortality for RCP8.5 is estimated to be 316 thousand deaths/year (likely due to an increase in methane emissions and to the net effect of climate change), while for the three other RCPs there is avoided ozone mortality between -718 thousand and -1.02 million deaths/year. For PM$_{2.5}$, avoided future premature mortality is estimated to be between -1.33 and -2.39 million deaths/year in 2100. These reductions in ambient air pollution-related mortality reflect the decline in most emissions projected in the RCPs. Mortality estimates differ among models and we find that, for most cases, the contribution to overall uncertainty from uncertainty associated with modeled air pollutant concentrations exceeds that from the RRs. Increases in exposed population and in baseline mortality rates of respiratory diseases magnify the impact on mortality of the changes in air pollutant concentrations. Estimating future mortality relative to 2000 concentrations allows us to emphasize the effects of changes in air pollution in these results. However, increases in exposed population and in baseline mortality rates may
drive an increase in the future burden of air pollution on mortality. Even in the most optimistic scenarios, the global mortality burden of ozone (relative to 1850 concentrations) is estimated to be over 1 million deaths/year in 2100, compared to less than 0.4 million in 2000 (Figure 8). For PM$_{2.5}$, the global burdens in 2030 and 2050 for the four RCPs are greater than the global burden in 2000: between 2.4 and 2.6 million deaths/year in 2030 and between 1.8 and 3.5 million deaths/year in 2050, compared to 1.7 million deaths/year in 2000 (Figure 9).

The RCPs are based on the premise that economic development drives better air pollution control, leading to improved air quality. This trend is apparent in some developing countries now (Klimont et al., 2013), but it is yet to be determined how aggressive many developing nations will be in addressing air pollution. The assumed link between economic development and air pollution control in the RCPs requires new and stronger regulations around the world, as well as new control technologies, for the air pollution decreases in the RCPs to be realized. The projected reductions in mortality estimated here will be compromised if more stringent policies are delayed (e.g., Lelieveld et al., 2015).

Acknowledgements

The research here described was funded by a fellowship from the Portuguese Foundation for Science and Technology, by a Dissertation Completion Fellowship from The Graduate School (UNC – Chapel Hill), and by NIEHS grant #1 R21 ES022600-01. We thank Karin Yeatts (Department of Epidemiology, UNC – Chapel Hill) for her help in researching projections of future population and baseline mortality rates, Colin Mathers (WHO) for advising us on the IFs, Peter Speyer (IHME, University of Washington) for providing us access to GBD2010 cause-specific mortality data at the country-level, and Amanda Henley (Davis Library Research & Instructional Services, UNC – Chapel Hill) for facilitating our access to Landscan 2011 Global Population Dataset. The work of DB and PC was funded by the U.S. Dept. of Energy (BER), performed under the auspices of LLNL under Contract DE-AC52-07NA27344, and used the supercomputing resources of NERSC under contract No. DE-AC02-05CH11231. Ruth Doherty, Ian MacKenzie and David Stevenson acknowledge ARCHER supercomputing resources and funding under the UK Natural Environment Research Council grant: NE/I008063/1.

References


Figure 1: Estimates of future ozone respiratory mortality for all RCP scenarios in 2030, 2050 and 2100, showing global mortality for 13 models and the multi-model average (million deaths/year), for future air pollutant concentrations relative to 2000 concentrations. Uncertainty for the multi-model average shown for RCP8.5 is the 95% CI including uncertainty in RR and across models. Only models with results for the three years have lines connecting the markers.
Figure 2: Future ozone respiratory mortality for all RCP scenarios in 2030, 2050 and 2100, showing the multi-model average in each grid cell, for future air pollutant concentrations relative to 2000 concentrations.
Figure 3: Future ozone respiratory mortality for all RCP scenarios in 2030, 2050 and 2100, showing the multi-model regional average (deaths/year) in ten world regions (Figure S1) and globally, for future air pollutant concentrations relative to 2000 concentrations.
Figure 4: Estimates of future premature mortality (IHD+STROKE+COPD+LC) for PM$_{2.5}$ calculated as a sum of species, for all RCP scenarios in 2030, 2050 and 2100, showing global mortality for six models and the multi-model average (million deaths/year), for future air pollutant concentrations relative to 2000 concentrations. Uncertainty shown for the RCP8.5 multi-model average is the 95% CI including uncertainty in RR and across models.
Figure 5: Future premature mortality (IHD+STROKE+COPD+LC) for PM$_{2.5}$ calculated as a sum of species, for all RCP scenarios in 2030, 2050 and 2100, showing the multi-model average in each grid cell, for future air pollutant concentrations relative to 2000 concentrations.
Figure 6: Future premature mortality (IHD + STROKE + COPD + LC) for PM2.5 calculated as a sum of species, for all RCP scenarios in 2030, 2050 and 2100, showing the multi-model regional average (deaths/year) in ten world regions (Figure S1) and globally, for future air pollutant concentrations relative to 2000 concentrations.

Figure 6: Future premature mortality (IHD + STROKE + COPD + LC) for PM2.5 calculated as a sum of species, for all RCP scenarios in 2030, 2050 and 2100, showing the multi-model regional average (deaths/year) in ten world regions (Figure S1) and globally, for future air pollutant concentrations relative to 2000 concentrations.
Figure 7: Estimates of global future premature mortality (IHD+STROKE+COPD+LC) for RCP8.5 in 2030 and 2100, for PM$_{2.5}$ reported by four models and PM$_{2.5}$ estimated as a sum of species for six models, showing global mortality for each model and the multi-model average (million deaths/year), for future air pollutant concentrations relative to 2000 concentrations. Models signaled with * reported their own estimate of PM$_{2.5}$. Uncertainty shown for six models for sum of species is the 95% CI including uncertainty in RR and across models.
Figure 8: Global burden on mortality of ozone concentrations relative to 1850, in the present day for 2000 concentrations, showing multi-model average and 95% CI including uncertainty in RR and across models (deaths/year), and in 2030, 2050 and 2100 for all RCPs, showing multi-model averages (deaths/year) given by the deterministic values. Also shown are future burdens using (Case A) 2000 concentrations relative to 1850 and present-day population but future baseline mortality rates and (Case B) 2000 concentrations relative to 1850 but future population and baseline mortality rates.

Figure 9: Global burden on mortality of PM2.5 concentrations relative to 1850, in the present day for 2000 concentrations, showing multi-model average and 95% CI including uncertainty in RR and across models (deaths/year), and in 2030, 2050 and 2100 for all RCPs, showing multi-model averages (deaths/year) given by the deterministic values. Also shown are future burdens using (Case A) 2000 concentrations relative to 1850 and present-day population but future baseline mortality rates and (Case B) 2000 concentrations relative to 1850 but future population and baseline mortality rates.